UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): May 24, 2017
MEDOVEX CORP.
(Exact
Name of Registrant as Specified in Charter)
|
Nevada
|
|
333-198621
|
|
46-3312262
|
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|
|
|
|
|
1950
Airport Road, Suite A
Atlanta,
Georgia
|
|
|
|
30341
|
|
(Address
of principal executive offices)
|
|
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (844) 633-6839
Copies
to:
Harvey
Kesner, Esq.
Arthur
S. Marcus, Esq.
Sichenzia
Ross Friedman Ference LLP
61
Broadway, 32nd Floor
New
York, New York 10006
(212)
930-9700
(212)
930-9725 (fax)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d 2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2) ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act ☐
On May
24, 2017, Medovex Corp. (the “Company”) filed a request
for an appeal in the form of an oral hearing of the determination
of the Listing Qualifications Department of the NASDAQ Stock Market
that it faces delisting of its securities on the Nasdaq Stock
Market as a result of its stockholders’ equity as reported in
its Form 10-Q for the quarter ended March 31, 2017 being below the
minimum stockholders’ equity of $2,500,000 required for
continued listing on the NASDAQ Capital Market as set forth in
NASDAQ listing rule 5550(b)(1) (the
“Rule”).
NASDAQ
granted the Company’s request for an oral hearing and has
scheduled the hearing for June 15, 2017. As a result, the
Company’s securities will not be suspended at the opening of
business on May 26, 2017.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
MEDOVEX CORP.
|
|
|
|
|
Date:
May 24, 2017
|
By:
/s/ Jarrett
Gorlin
Jarrett
Gorlin
Chief
Executive Officer
|